Table 5.
Ongoing trials of neuraminidase inhibitors for influenza in children
| Identifier | Methods | Participants | Interventions | Outcomes | Details |
|---|---|---|---|---|---|
| NCT00412737 | Seasonal prophylaxis for 12 weeks | Transplant recipients. Age >1. Negative for influenza. Confirmed influenza | Oseltamivir v placebo | Primary: percentage of patients with laboratory confirmed clinical influenza | CD: Nov 2008. Hoffmann-La Roche |
| NCT00593502 | Prevention of otitis media in young otherwise healthy children with symptomatic influenza | Age 1. Healthy children. Confirmed influenza .Within 24 hours of symptoms | Oseltamivir v placebo | Primary: incidence of otitis media. Secondary: time to resolution of fever and other symptoms | CD: June 2009. Hospital District of Southwestern Finland. Hoffmann-La Roche |
| NCT00555893 | Treatment <48 h v >48 h after symptoms | Age >1. Clinical influenza | Oseltamivir v placebo | Primary: duration of influenza illness. Secondary: secondary attack rate, secondary complications | ECD: Feb 2011. Marshfield Clinic Research Foundation |
| NCT00707941 | Treatment <48 h v >48 h after symptoms, and placebo | Age >1. Population: Bangladesh, urban slum. Confirmed influenza | Oseltamivir v placebo | Primary: duration of clinical illness, clinical complications | ECD: Dec 2009. International Centre for Diarrhoeal Disease Research, Bangladesh |
| NCT00545532 | Standard v high dose oseltamivir in transplant recipients | Age >1. Transplant recipients on immunosuppression. Confirmed influenza. Treatment <48h | Oseltamivir standard v high dose. | Primary: time to alleviation of all clinical symptoms. Secondary: secondary illness/complications | ECD: Oct 2010. Hoffmann-La Roche |
| NCT00867139 | Triple combined antivirals v monotherapy for influenza A in immunocompromised participants | Age ≥7. Immunocompromised. Confirmed influenza | Amantadine + ribavirin + oseltamivir v zanamivir or oseltamivir | Primary: safety. Secondary: duration of symptoms | ECD: Dec 2010. Fred Hutchinson Cancer Research Center |
| NCT00298233 | Standard v high dose oseltamivir in severe or avian influenza | Age >1 (some centres). Severe symptoms or avian influenza. Confirmed influenza | Oseltamivir; standard v high dose | Primary: negative RT-PCR from nasal swabs. Secondary: includes frequency of clinical failure | CD: Feb 2009. National Institute of Allergy and Infectious Diseases |
CD=completion date; ECD=estimated completion date.